| Budget Amount *help |
¥3,900,000 (Direct Cost: ¥3,000,000、Indirect Cost: ¥900,000)
Fiscal Year 2015: ¥1,170,000 (Direct Cost: ¥900,000、Indirect Cost: ¥270,000)
Fiscal Year 2014: ¥1,170,000 (Direct Cost: ¥900,000、Indirect Cost: ¥270,000)
Fiscal Year 2013: ¥1,560,000 (Direct Cost: ¥1,200,000、Indirect Cost: ¥360,000)
|
|---|
| Outline of Final Research Achievements |
Previous pathological studies confirmed the presence of heterogeneity in remyelination capacity among multiple sclerosis patients and such capacity may influence the prognosis of the disease. Due to the lack of clinically feasible methods to visualize remyelination, the proof of such heterogeneity in real world clinical practice has been difficult. The researchers recently succeeded to develop a new MRI modality (Myelin Mapping) to visualize myelin for the purpose. In the current study, a clinical study was performed for multiple sclerosis patients to apply the modality, and results suggested that the heterogeneity of remyelination capacity does exist in multiple sclerosis and that such capacity may be influenced by administration of certain drugs.
|
